Bionano Announces Full Commercial Release Of The Stratys System For High Throughput Optical Genome Mapping
Portfolio Pulse from Benzinga Newsdesk
Bionano Genomics, Inc. (NASDAQ:BNGO) has announced the full commercial release of the Stratys system for high throughput optical genome mapping (OGM). The Stratys system offers up to four times the data generation rate of the Saphyr instrument and supports up to 12 single access chips. It is powered by Stratys Compute, developed with NVIDIA. The system has been adopted by 10 users across Canada, the US, Europe, and Saudi Arabia, with 11 systems in use. The Stratys system is designed for increased flexibility and throughput, compatible with G2 chemistries, and has a potential 3-day sample-to-answer time for hematological samples. It is expected to transform lab approaches to genome analysis and has seen orders exceeding the initial offering during its early access program.
January 23, 2024 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bionano's full commercial release of the Stratys system could lead to increased sales and market penetration, enhancing the company's revenue prospects and solidifying its position in the genomics market.
The commercial release of a new product, especially one that improves upon previous technology and has already seen enthusiasm in its early access program, is likely to be viewed positively by investors. The Stratys system's increased throughput and flexibility, along with its compatibility with G2 chemistries, position Bionano to capture more of the genomics market, potentially leading to increased sales and revenue. The partnership with NVIDIA for the Stratys Compute workstation also adds credibility and could be a catalyst for further adoption.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100